.jpg "Analysts")
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Heron Therapeutics (NASDAQ: HRTX) and Pieris Pharmaceuticals (NASDAQ: PIRS) with bullish sentiments.
Heron Therapeutics (NASDAQ: HRTX)
In a report released today, Louise Chen from Cantor Fitzgerald reiterated a Buy rating on Heron Therapeutics (NASDAQ: HRTX), with a price target of $40. The company’s shares opened today at $30.70, close to its 52-week high of $32.70.
Chen wrote:
“Positives from the quarter that support our thesis: 1) On 03/19/18, HRTX announced positive topline results from its completed Phase 3 studies of the investigational agent HTX-011 in subjects undergoing bunionectomy (Study 301/EPOCH1) and hernia repair (Study 302/EPOCH2).”
According to TipRanks.com, Chen is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -10.3% and a 37.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Paratek Pharmaceuticals, and Spero Therapeutics Inc.
Currently, the analyst consensus on Heron Therapeutics is Strong Buy and the average price target is $41.90, representing a 36.5% upside.
In a report issued on May 8, Cowen & Co. also maintained a Buy rating on the stock with a $48 price target.
See today’s analyst top recommended stocks >>
Pieris Pharmaceuticals (NASDAQ: PIRS)
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Pieris Pharmaceuticals (NASDAQ: PIRS) today and set a price target of $12. The company’s shares opened today at $5.69.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -13.0% and a 34.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Currently, the analyst consensus on Pieris Pharmaceuticals is Strong Buy and the average price target is $11.50, representing a 102.1% upside.
In a report issued on May 4, Cowen & Co. also initiated coverage with a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
